Karim F, Shaikh U, Adil SN, Khurshid M
Correspondence: Dr Farheen Karim, farheen.mahar@aku.edu
ABSTRACT
INTRODUCTION Acute promyelocytic leukaemia (APL) is a distinct clinical and biological subtype of acute myeloid leukaemia. APL is notorious for causing early death during induction therapy, resulting in induction failure. The aim of our study was to report the clinical characteristics, outcome and early induction deaths with regard to patients with APL seen at our hospital.
METHODS This was a retrospective study carried out at Aga Khan University Hospital, Karachi, Pakistan. Patients aged > 15 years diagnosed with APL within the period September 2007–September 2012 were included in the study.
RESULTS Within the study period, 26 patients were diagnosed with APL based on morphology and the detection of t(15;17)(q24.1;q21.1) and promyelocytic leukaemia-retinoic acid receptor alpha (PML-RARA). The male to female ratio was 1:1. The median age of the patients was 41 (range 16–72) years. In all, there were 13 (50.0%) high-risk patients, and early induction death rate was 61.5%. Causes of early induction deaths (n = 16) included haemorrhage in 7 (43.8%) patients, differentiation (ATRA) syndrome in 7 (43.8%) and infection in 2 (12.5%). The survival rate among patients who survived the early period was 70% at 42 months. The relapse rate was 30%.
CONCLUSION Early induction death rate was very high in patients with APL. The most common cause of early induction death in our study was haemorrhage. Outcome among patients with APL was found to be better among those who survived the initial period.
Keywords: adults, death, early, leukaemia, promyelocytic
Singapore Med J 2014; 55(8): 443-447; http://dx.doi.org/10.11622/smedj.2014105
REFERENCES
1. Walter RB, Othus M, Burnett AK, et al. Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood 2003; 121:2424-31. http://dx.doi.org/10.1182/blood-2012-10-462440 | ||||
2. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985 Oct; 103:620-5. http://dx.doi.org/10.7326/0003-4819-103-4-620 | ||||
3. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press, 2008. | ||||
4. Stanley M, McKenna RW, Ellinger G, Brunning RD. Classification of 358 Cases of Acute Myeloid Leukemia by FAB Criteria: Analysis of Clinical and Morphologic Features. In: Bloomfield CD, ed. Chronic and Acute Leukemias in Adults. Boston: Martinus Nijhoff Publishers, 1985: 147–74. http://dx.doi.org/10.1007/978-1-4613-2581-9_5 | ||||
5. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113:1875-91. http://dx.doi.org/10.1182/blood-2008-04-150250 | ||||
6. Candoni A, Damiani D, Michelutti A, et al. Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia. Eur J Haematol 2003; 71:1-8. http://dx.doi.org/10.1034/j.1600-0609.2003.00084.x | ||||
7. Golomb HM, Rowley JD, Vardiman JW, Testa HR, Butler A. "Microgranular" acute promyelocytic leukemia: a distinct clinical, ultrastructural, and cytogenetic entity. Blood 1980; 55:253-9. PMid:6928105 | ||||
8. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72:567-72. PMid:3165295 | ||||
9. Zhang L, Zhu X. Epidemiology, diagnosis and treatment of acute promyelocytic leukemia in children: the experience in China. Mediterr J Hematol Infect Dis 2012; 4:e2012012. http://dx.doi.org/10.4084/mjhid.2012.012 | ||||
10. Tallman MS, Nabhan C. Management of acute promyelocytic leukemia. Curr Oncol Rep 2002; 4:381-9. http://dx.doi.org/10.1007/s11912-002-0031-1 | ||||
11. Douer D. Advances in the treatment of relapsed acute promyelocytic leukemia. Acta Haematol 2002; 107:1-17. http://dx.doi.org/10.1159/000046623 | ||||
12. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99:759-67. http://dx.doi.org/10.1182/blood.V99.3.759 | ||||
13. Sanz MA, Martín G, Lo Coco F. Choice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukemia. Best Pract Res Clin Haematol 2003; 16:433-51. http://dx.doi.org/10.1016/S1521-6926(03)00040-9 | ||||
14. Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood 2009; 114:5126-35. http://dx.doi.org/10.1182/blood-2009-07-216457 | ||||
15. Di Bona E, Avvisati G, Castaman G, et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukemia. Br J Haematol 2000; 108:689-95. http://dx.doi.org/10.1046/j.1365-2141.2000.01936.x | ||||
16. Hillestad LK. Acute promyelocytic leukemia. Acta Med Scand 1957; 159:189-94. http://dx.doi.org/10.1111/j.0954-6820.1957.tb00124.x | ||||
17. Rovelli A, Biondi A, Cantù Rajnoldi A, et al. Microgranular variant of acute promyelocytic leukemia in children. J Clin Oncol 1992; 10:1413-8. PMid:1517784 | ||||
18. Tallman MS, Brenner B, Serna Jde L, et al. Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom. Leuk Res 2005; 29:347-51. http://dx.doi.org/10.1016/j.leukres.2004.04.021 | ||||
19. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008; 111:3395-402. http://dx.doi.org/10.1182/blood-2007-07-100669 | ||||
20. Serefhanoglu S, Buyukasik Y, Goker H, et al. Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy. Leuk Res 2010; 34:e317-9. http://dx.doi.org/10.1016/j.leukres.2010.07.027 | ||||
21. Sanz MA, Martín G, González M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study of the PETHEMA group. Blood 2004; 103:1237-43. http://dx.doi.org/10.1182/blood-2003-07-2462 | ||||
22. Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia 2011; 25:1128-34. http://dx.doi.org/10.1038/leu.2011.78 | ||||
23. Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011: 118:1248-54. http://dx.doi.org/10.1182/blood-2011-04-346437 | ||||
24. Esteve J, Escoda L, Martín G, et al. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia 2007; 21:446-52. http://dx.doi.org/10.1038/sj.leu.2404501 | ||||
25. Avvisati G, Lo Coco F, Diverio D, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996; 88:1390-8. PMid:8695858 | ||||
26. Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood 2011; 117:4716-25. http://dx.doi.org/10.1182/blood-2010-08-302950 | ||||
27. Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009; 113:775-83. http://dx.doi.org/10.1182/blood-2008-07-168617 | ||||
28. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111:2505-15. http://dx.doi.org/10.1182/blood-2007-07-102798 | ||||
29. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 100:4298-302. http://dx.doi.org/10.1182/blood-2002-02-0632 | ||||
30. Jacomo RH, Melo RA, Souto RF, et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica 2007; 92:1431-2. http://dx.doi.org/10.3324/haematol.10874 | ||||
31. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90:1014-21. PMid:9242531 | ||||
32. Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood 1995; 85:1202-6. PMid:7858250 | ||||
33. Raza S, Ullah K, Ahmed P, Khan B. Comparison of anthracycline-based combination chemotherapy with or without all-trans retinoic acid in acute promyelocytic leukemia. J Coll Physicians Surg Pak 2008; 18:546-50. PMid:18803891 | ||||
34. Pagoni M, Garofalaki M, Panitsas F, et al. Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era. Mediterr J Hematol Infect Dis 2011; 3:e2011053. http://dx.doi.org/10.4084/mjhid.2011.053 | ||||
35. Mitrovic M, Suvajdzic N, Bogdanovic A, et al. International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation ≥ 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia. Med Oncol 2013; 30:478. http://dx.doi.org/10.1007/s12032-013-0478-y | ||||
36. Sanz MA, Montesinos P, Rayón C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010; 115:5137-46. http://dx.doi.org/10.1182/blood-2010-01-266007 | ||||
37. Au WY, Fung A, Chim CS, et al. FLT-3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact. Br J Haematol 2004; 125:463-9. http://dx.doi.org/10.1111/j.1365-2141.2004.04935.x |